<DOC>
	<DOCNO>NCT02777268</DOCNO>
	<brief_summary>This single centre , open-label , randomised , 5-way crossover study .</brief_summary>
	<brief_title>Comparison Pharmacokinetics Infacort® Versus Immediate-release Hydrocortisone</brief_title>
	<detailed_description>This single centre , open-label , randomised , 5-way crossover study design compare PK Infacort® versus immediate-release hydrocortisone tablet evaluate dose proportionality 0.5 mg , 2 mg , 5 mg 10 mg Infacort® . The study conduct 1 cohort 16 healthy male subject comprise Screening Visit , 5 treatment period ( Treatment Periods 1 5 ) Post-study Visit .</detailed_description>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Healthy male volunteer 18 60 year age , inclusive ( Screening Visit ) . Subjects Body Mass Index ( BMI ) 2128 . Subjects clinically significant abnormal serum biochemistry , haematology urine examination value within 14 day prior first dose investigational medicinal product ( IMP ) . Subjects negative urinary drug abuse screen determine within 14 day prior first dose IMP . A positive alcohol test may repeat discretion Investigator . Subjects negative human immunodeficiency virus ( HIV ) hepatitis B surface antigen ( Hep B ) hepatitis C virus antibody ( Hep C ) result . Subjects clinically significant abnormality 12lead electrocardiogram ( ECG ) determine within 14 day prior first dose IMP . Subjects clinicallysignificant deviation outside normal range blood pressure pulse measurement . Subjects ( unless anatomically sterile abstain sexual intercourse inline prefer usual lifestyle subject ) sexual partner use effective contraception method trial 3 month last dose IMP , example ; oral contraceptive + condom , intrauterine device ( IUD ) + condom diaphragm spermicide + condom . Subjects available complete study . Subjects satisfy medical examiner fitness participate study . Subjects provide write informed consent participate study . A clinically significant history gastrointestinal disorder likely influence drug absorption . Receipt regular medication within 14 day prior first dose IMP ( include high dose vitamin , dietary supplement herbal remedy ) . Receipt vaccination within 14 day prior first dose IMP . Evidence renal , hepatic , central nervous system , respiratory , cardiovascular metabolic dysfunction . Presence clinically significant infection ( systemic fungal viral infection , acute bacterial infection ) . Current previous history tuberculosis . A clinically significant history previous allergy / sensitivity hydrocortisone and/or dexamethasone . A clinically significant history family history psychiatric disorders/illnesses . A clinically significant history drug alcohol abuse . Inability communicate well Investigator ( i.e. , language problem , poor mental development impair cerebral function ) . Participated New Chemical Entity clinical study within previous 4 month market drug clinical study within previous 3 month . ( N.B . The washout period trial define period time elapse last dose previous study first dose next study ) . Subjects consume 2 unit alcohol per day within 7 day prior first dose IMP consume alcohol within 48 hr period prior first dose IMP . Donation 450 mL blood within previous 3 month . Subjects smoke ( exsmokers smoke within 6 month prior first dose IMP ) . Subjects work shift ( i.e . regularly alternated day , afternoon night ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>